| Diabetes |
 |
Strategic analysis of Takeda’s NIDDM pipeline portfolio |
|
Strategies and trial protocols of post-market outcomes studies for a GLP-1 analog |
|
In-depth protocol assessments of two, Phase III DPP-IV inhibitors |
|
Assessments of Phase III trials and launch strategies of a dual-PPAR and a pan-PPAR |
|
Assessments of a glucokinase activator’s 11 Phase II trials |
| |
|
Reasons for its discontinuation, future plans |
|
|
Development strategies at four Pharma companies involving RNAi as an antidiabetic
mechanism |
|
Analysis of the turf war between cardiologists and endocrinologists concerning
the diabetes category |
| |
|
Strategic implications |
|
Economic implications |
|
New opportunities |
|
Trial design implications |
|
Use of the “wrong” surrogate markers? |
|
|
Opportunities and challenges related to developing a consumer database marketing
component of a diabetes franchise |
|
Credibility and persuasiveness of the dual-PPAR core message |
|
Perceived relevance of client’s satellite symposia at recent ADA meeting |
|
Reasons for disdaining the cardio-metabolic syndrome concept |
|
Level of early conceptual appeal of SGLT-2 inhibitors |
|
Whether DPP-IV inhibitors represent a therapeutic advance or planned obsolescence |
|
Responsiveness to new positioning and segmentation strategy for marketing GLP-1
analogs |
|
More than 30 projects in blood glucose monitoring |
| |
|
Executive dossiers and management style profiles |
|
Competitive technology assessments |
|
Distribution studies |
|
Strategic launch assessments |
|
Regulatory affairs analyses |
|
Threat identification, evaluation and counter-measure planning |
|
| Vaccines |
|
Status of EU development on a hexavalent, meninge B vaccine |
|
Assessment and timeline associated with initiating U.S. trials |
|
Analysis of pricing disparities among physician supply houses for assessing new approaches
to vaccine distribution |
|
Evaluation of current generation efforts to develop AIDS vaccines |
|
Advantages and disadvantages associated with developing a new vaccine dosed outside
the current schedule of baby well-checks and vaccinations |
|
Opportunities for utilizing local physician supply houses in an innovative manner
related to vaccine orders placed through a manufacturer's web site |
|
Assessment of methods for implementing and tracking vaccine utilization in correctional
facilities |
|
Evaluation of reasons for non-participation by selected hospitals in a vaccine-and-antibiotic
bundling deal offered through a major GPO; |
| Rheumatology |
|
Benefits and risks associated with promoting an anti-rheumatoid DMARD product to
PCPs |
|
Assessment of provider approaches for obtaining third-party reimbursement on a rigorous
physical therapy and dietary program to treat osteoarthritis |
|
An assessment of selected methods for redirecting the current approaches of specified
MCOs to limiting the usage of COX-2 inhibitors |
|
Evaluations of an approach to mollifying concerns among rhematologists relative to
TNF inhibitors that increase susceptibility to infection |
| Dermatology |
|
Opportunities, barriers and pricing dilemmas associated with developing two retinoid
products for acne |
|
Potential of dermatologists augmenting sales of an oral contraceptive promoted for
its ancillary skin benefits |
|
Evaluation of consumer choice patterns in selecting either self-medication, a PCP
or a dermatologist for mild-to-moderate acne |
| Cardiovascular |
|
Evaluation of late-stage clinical trials for anti-arrythmic products |
|
Development strategies among anti-platelet drugs |
|
(Anti-diabetic products) Assessment of clinical trials and launch strategies for
new, oral anti-diabetics: dual- and pan-PPARs, incretin mimetics, DPP-IV inhibitors |
|
Costs and benefits associated with initiating Phase III trials on a thrombolytic |
|
Credibility associated with using a moribund compound for treating atrial arrhythmias |
|
Obstacles confronting the intravenous IIb/IIIa antagonists as anti-anginal agents |
|
Opportunities and impediments to increasing the usage of IV corticosteroids by ER
physicians following ischemic stroke |
|
Obstacles to expanding the market for thrombolytics in ischemic stroke: an assessment
of the political dynamics between neurologists and ER physicians |
|
Opportunities, barriers and pricing dilemmas for a product capable of preventing
both DVT and atrial fibrillation |
|
An assessment of morale among investigators to a manufacturer's decision about embargoing
trial results on an antihypertensive-CHF product |
|
Attitudes among the major CV competitors relative to developing fixed-dose combinations
of antihypertensives and other, non-diuretic compounds |
|
An assessment of the clinical trials and launch strategy of a non-benzodiazepine
anxiolytic |
| Behavioral/Psychiatric |
|
Opportunities and impediments associated with marketing SSRIs for social phobias
in children |
|
Opportunities for an anti-seizure product as an anti-depressant adjunct |
|
Obstacles confronting the use of an anti-narcolepsy product as an anti-depressant
adjunct |
|
An ethnographic evaluation of sexual, cardiovascular and mood side effects among
SSRI users |
|
Assessment of EU and US market opportunities for a 5-HT2 receptor antagonist to treat
generalized anxiety disorder |
|
Opportunities and obstacles facing the development of antidepressants and antipsychotics
that affect multiple neurotransmitters |
|
The passing of "selectivity" as a differentiating advance among thought-leading
psychopharmacologists |
| Infectious Disease |
|
Assessments of current and pipeline products for treating hepatitis C |
|
Analysis of a tendency among GI specialists, despite their denials, to warehouse
hepatitis C patients until the launches of the pegylated versions |
|
Opportunities among internists for displacing a leading, broad spectrum, oral antibiotic
with a new, intravaginally administered product |
|
Phase III trials assessment and launch strategy for an anti-sepsis product |
|
The use of unobtrusive measures to assess what ID specialists and PCPs really think
about minimal GI distress as a competitive feature in oral quinolones |
|
Promoting an AIDS-wasting product to PCPs |
|
An assessment among thought-leading GI specialists of treatment options for hepatitis
C |
|
An assessment of clinical trials and market potential for a potent anti-infective
for treating vancomycin-resistant sepsis |
|
An evaluation of key competitive issues in the hepatitis C market |
| Neurology |
|
Market opportunities for treating mild cognitive impairment with an existing CNS
product |
|
Willingness of neurologists in three countries to use an existing CNS product for
Parkinson's if it can obtain a neuro-protective labeling |
|
The market among neurologists for botulinum toxin as a migraine prophylactic |
|
Assessment of current efforts toward developing products for treating primary progressive
MS |
|
Opportunities for using an anti-seizure product as a migraine therapy |
|
How palliative is the current generation of Alzheimer's products: a qualitative assessment
among 200 neurologists |
|
Market potential of selected products in development for mild cognitive impairment |
|
Market opportunities for treating early stage Alzheimer's with an existing CNS product |
| Oncology |
|
Cocktail approaches for anti-angiogenesis compounds favored by oncologists who prefer
therapies not under protocol |
|
Development status of viral vectors as oncology vaccines |
|
Interest levels of oncologists toward a viral vector product approved with a time-to-progression
endpoint instead of overall mortality |
|
The market for promoting a SERM indicated to prevent osteoporosis as a product to
reduce the chances of breast cancer |
|
Analysis of the unique pre-launch versus post-launch marketing spend and programs
in oncology compared to other therapeutic categories |
|
An assessment of diverse approaches to managing the development and registration
of signal inhibitors, anti-angiogenics and apoptosis inducers |
| Respiratory |
|
Evaluation of formulary acceptability and obstacles to MCO reimbursement confronting
a breath-actuated inhaler system |
|
Evaluation of consumer pull-through benefits from promoting the IgE receptor blocking
mechanism to allergic rhinitis patients |
|
Awareness and early assessments of thought leaders regarding the development of selected
compounds for bronchial asthma |
|
Assessment of selected approaches for overcoming impediments to thrombolytic usage
in COPD |
|
Market impediments to monoclonal antibody therapies in moderate to severe asthma |
|
Attitudes among thought leading, academic allergists regarding the use of low dose,
mood altering (anxiolytic, antidepressant) products as adjuncts to early stage, allergy
treatment |
|
An analysis of disputed market assumptions concerning opportunities for newer COPD
products |
| Women's Health |
|
Obstacles to greater use of SERMs and bisphosphonates by internists for osteoporosis
prevention and treatment |
|
Potential of dermatologists augmenting sales of an oral contraceptive promoted for
its ancillary skin benefits |
|
ROI associated with promoting a SERM indicated for osteoporosis as a product to reduce
the chances for getting breast cancer |
|
Approaches to developing preferential loyalty to a manufacturer's oral contraceptives,
HRT and other women's products by targeting female OB/GYNs |
|
An ethnographic study to assess opportunities and risks associated with communicating
a message to PCPs that cardiovascular disease among women constitutes a special sub-category |
|
Revenue margins, strategies, success factors and current R&D directions in the
oral contraceptive and hormone replacement therapy markets |
| Blood Products |
|
Regulatory status of Company X's Alpha1-Proteinase inhibitor |
|
Development status of competitors in the fibrin sealant category |
|
Assessment of co-development opportunities in the Factor VIII and Factor IX categories |
|
Analysis of transgenic development activities by Company Y |
